» Articles » PMID: 37729596

Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL

Abstract

Purpose: High hyperdiploidy, the largest and favorable subtype of childhood ALL, exhibits significant biological and prognostic heterogeneity. However, factors contributing to the varied treatment response and the optimal definition of hyperdiploidy remain uncertain.

Methods: We analyzed outcomes of patients treated on two consecutive frontline ALL protocols, using six different definitions of hyperdiploidy: chromosome number 51-67 (Chr51-67); DNA index (DI; DI1.16-1.6); United Kingdom ALL study group low-risk hyperdiploid, either trisomy of chromosomes 17 and 18 or +17 or +18 in the absence of +5 and +20; single trisomy of chromosome 18; double trisomy of chromosomes 4 and 10; and triple trisomy (TT) of chromosomes 4, 10, and 17. Additionally, we characterized ALL ex vivo pharmacotypes across eight main cytotoxic drugs.

Results: Among 1,096 patients analyzed, 915 had B-ALL and 634 had pharmacotyping performed. In univariate analysis, TT emerged as the most favorable criterion for event-free survival (EFS; 10-year EFS, 97.3% 86.8%; = .0003) and cumulative incidence of relapse (CIR; 10-year CIR, 1.4% 8.8%; = .002) compared with the remaining B-ALL. In multivariable analysis, accounting for patient numbers using the akaike information criterion (AIC), DI1.16-1.6 was the most favorable criterion, exhibiting the best AIC for both EFS (hazard ratio [HR], 0.45; 95% CI, 0.23 to 0.88) and CIR (HR, 0.45; 95% CI, 0.21 to 0.99). Hyperdiploidy and subgroups with favorable prognoses exhibited notable sensitivities to asparaginase and mercaptopurine. Specifically, asparaginase sensitivity was associated with trisomy of chromosomes 16 and 17, whereas mercaptopurine sensitivity was linked to gains of chromosomes 14 and 17.

Conclusion: Among different definitions of hyperdiploid ALL, DI is optimal based on independent prognostic impact and also the large proportion of low-risk patients identified. Hyperdiploid ALL exhibited particular sensitivities to asparaginase and mercaptopurine, with chromosome-specific associations.

Citing Articles

Recent Developments and Evolving Therapeutic Strategies in KMT2A-Rearranged Acute Leukemia.

Yin L, Wan L, Zhang Y, Hua S, Shao X Cancer Med. 2024; 13(20):e70326.

PMID: 39428967 PMC: 11491690. DOI: 10.1002/cam4.70326.


Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.

Purvis K, Zhou Y, Karol S, Rubnitz J, Ribeiro R, Lee S Blood. 2024; 145(2):190-201.

PMID: 39316653 PMC: 11738036. DOI: 10.1182/blood.2024024936.


Insights into the Clinical, Biological and Therapeutic Impact of Copy Number Alteration in Cancer.

Carey-Smith S, Kotecha R, Cheung L, Malinge S Int J Mol Sci. 2024; 25(13).

PMID: 38999925 PMC: 11241182. DOI: 10.3390/ijms25136815.


Diagnostic and treatment strategies for pediatric acute lymphoblastic leukemia in low- and middle-income countries.

Rujkijyanont P, Inaba H Leukemia. 2024; 38(8):1649-1662.

PMID: 38762553 DOI: 10.1038/s41375-024-02277-9.


Gene expression prognostic of early relapse risk in low-risk B-cell acute lymphoblastic leukaemia in children.

Gong X, Hu T, Shen Q, Zhang L, Zhang W, Liu X EJHaem. 2024; 5(2):333-345.

PMID: 38633121 PMC: 11020147. DOI: 10.1002/jha2.872.

References
1.
Teachey D, Pui C . Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol. 2019; 20(3):e142-e154. PMC: 9233195. DOI: 10.1016/S1470-2045(19)30031-2. View

2.
Paulsson K, Forestier E, Lilljebjorn H, Heldrup J, Behrendtz M, Young B . Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010; 107(50):21719-24. PMC: 3003126. DOI: 10.1073/pnas.1006981107. View

3.
Harris M, Shuster J, Carroll A, Look A, Borowitz M, Crist W . Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood. 1992; 79(12):3316-24. View

4.
Uckun F, Kersey J, Heerema N, Provisor A, Haag D, Gilchrist G . Heterogeneity of cultured leukemic lymphoid progenitor cells from B cell precursor acute lymphoblastic leukemia (ALL) patients. J Clin Invest. 1987; 80(3):639-46. PMC: 442285. DOI: 10.1172/JCI113116. View

5.
Arico M, Valsecchi M, Rizzari C, Barisone E, Biondi A, Casale F . Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol. 2008; 26(2):283-9. DOI: 10.1200/JCO.2007.12.3927. View